Vir Biotechnology, Inc.

This early-stage trial tests a new drug called VIR-5818, alone or with another drug (pembrolizumab), in people with advanced HER2-expressing cancers that have spread. The main goals are to check safety and find the right dose. About 645 adults with various HER2-positive tumors wi…

This early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…

This study tests whether a combination of two experimental drugs (tobevibart and elebsiran) can clear or lower hepatitis D virus in adults who still have detectable virus despite taking bulevirtide. About 150 participants will receive the combination and be followed for up to 240…

This early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatments. The main goals are to check safety, find the right dose, and see if it can shrink tumors or lower PSA levels. About 437 participants …